<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846180</url>
  </required_header>
  <id_info>
    <org_study_id>XHNKKY-VASO 2.0</org_study_id>
    <nct_id>NCT03846180</nct_id>
  </id_info>
  <brief_title>Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage</brief_title>
  <official_title>Terlipressin Versus Somatostatin/Octreotide on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage (TORCH): A Retrospective Multicenter Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Terlipressin and somatostatin/octreotide are the first-line choices for the treatment of
      acute variceal bleeding in liver cirrhosis. Acute kidney injury can develop in patients
      presenting with acute variceal bleeding. On the other hand, evidence suggests that
      terlipressin can reverse hepatorenal syndrome. It has been hypothesized that terlipressin can
      protect the renal function in cirrhotic patients with acute variceal bleeding, except for
      control of bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ICA-AKI and kidney function damage in cirrhotic patients with acute gastrointestinal bleeding</measure>
    <time_frame>Through study completion, an average of 1-2 weeks</time_frame>
    <description>ICA-AKI and kidney function damage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of ICA-AKI and kidney function damage on in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding</measure>
    <time_frame>Through study completion, an average of 1-2 weeks</time_frame>
    <description>In-hospital mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of terlipressin on the in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding with ICA-AKI and kidney function damage</measure>
    <time_frame>Through study completion, an average of 1-2 weeks</time_frame>
    <description>In-hospital mortality associated with ICA-AKI and kidney function damage</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1682</enrollment>
  <condition>Variceal Hemorrhage</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Terlipressin group</arm_group_label>
    <description>Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Somatostatin/Octreotide group</arm_group_label>
    <description>Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Continuous or intermittent intravenous infusion of terlipressin was given.</description>
    <arm_group_label>Terlipressin group</arm_group_label>
    <other_name>Glypressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <description>Continuous or intermittent intravenous infusion of somatostatin was given.</description>
    <arm_group_label>Somatostatin/Octreotide group</arm_group_label>
    <other_name>Stilamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Continuous or intermittent intravenous infusion of octreotide was given.</description>
    <arm_group_label>Somatostatin/Octreotide group</arm_group_label>
    <other_name>Sandostatin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cirrhotic patients with acute gastrointestinal bleeding received terlipressin or
        somatostatin/octreotide.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cirrhotic patients who were admitted between January 2010 and December 2018.

          2. A diagnosis of acute gastrointestinal bleeding.

          3. Patients who received terlipressin or somatostatin/octreotide.

          4. Age or sex was not limited.

          5. Use of endoscopy was not limited.

          6. Comorbidity was not limited.

          7. Malignancy was not limited.

        Exclusion Criteria:

          1. Renal parenchymal diseases.

          2. Absence of baseline serum creatinine.

          3. Absence of serum creatinine 3-5 days after terlipressin or somatostatin/octreotide.

          4. Duration of terlipressin or somatostatin/octreotide was less 3 days.

          5. Patients who underwent transjugular intrahepatic portosystemic shunt.

          6. Patients who underwent surgical shunt, splenectomy with or without devascularization,
             or liver transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Liver Cirrhosis, The Fifth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Difficult &amp; Complicated Liver Diseases and Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Research Center, The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hepatobiliary Disease, 900 Hospital of the Joint Logistics Team (formerly called Fuzhou General Hospital)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, The First Affiliated Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, The Sixth People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Air Force Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110840</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Xi'an Central Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Hospital of the Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, General Hospital of Western Theater Command</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang J, Rössle M, Zhou X, Deng J, Liu L, Qi X. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence. Curr Med Res Opin. 2019 May;35(5):859-868. doi: 10.1080/03007995.2018.1552575. Epub 2019 Jan 4. Review.</citation>
    <PMID>30474439</PMID>
  </reference>
  <reference>
    <citation>Zhou X, Tripathi D, Song T, Shao L, Han B, Zhu J, Han D, Liu F, Qi X. Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Nov;97(48):e13437. doi: 10.1097/MD.0000000000013437.</citation>
    <PMID>30508958</PMID>
  </reference>
  <reference>
    <citation>Zhou XM, Qi XS, Jia JD. [An evidence-based terlipressin therapy for gastroesophageal variceal hemorrhage]. Zhonghua Gan Zang Bing Za Zhi. 2018 Apr 20;26(4):245-248. doi: 10.3760/cma.j.issn.1007-3418.2018.04.002. Chinese.</citation>
    <PMID>29996332</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Xingshun Qi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This plan to share the individual patient data has been not decided yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

